TOP TEN perturbations for 38570_at (Homo sapiens)

Organism: Homo sapiens
Gene: 38570_at
Selected probe(set): 205671_s_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array

Expression of 38570_at (205671_s_at) across 6674 perturbations tested by GENEVESTIGATOR:

CML study 1 / B-CLL study 5

Relative Expression (log2-ratio):-4.5167303
Number of Samples:75 / 441
Experimental CML study 1
Bone marrow samples of patients with chronic myeloid leukemia (CML).
Control B-CLL study 5
Bone marrow samples of patients with B-cell chronic lymphocytic leukemia (B-CLL).

ovulation study 1 / proliferative phase endometrium tissue

Relative Expression (log2-ratio):4.1840334
Number of Samples:3 / 4
Experimental ovulation study 1
Early secretory phase (ESE) endometrium tissue.
Control proliferative phase endometrium tissue
Proliferative phase (PE) endometrium tissue.

uterine/pelvic pathology study 2 (late se MCP) / uterine/pelvic pathology study 2 (early se MCP)

Relative Expression (log2-ratio):-4.1598177
Number of Samples:2 / 6
Experimental uterine/pelvic pathology study 2 (late se MCP)
Endometrial tissue samples collected from women with uterine/pelvic pathology in the late secretory menstrual cycle phase (MCP). The group contained cycling women 20 – 50 years old with symptomatic uterine fibroids, pelvic organ prolapse, and adenomyosis. The MCP was determined by endometrial histology, confirmed by estradiol and progesterone serum levels and corroborated by 2 independent bioinformatics methods: clustering in unsupervised whole-transcriptome principal component analysis and cycle phase assignment classifier analysis. Patients with hormonal treatment within previous 3 months and presence of malignancy or major systemic disease were excluded.
Control uterine/pelvic pathology study 2 (early se MCP)
Endometrial tissue samples collected from women with uterine/pelvic pathology in the early secretory menstrual cycle phase (MCP). The group contained cycling women 20 – 50 years old with symptomatic uterine fibroids, pelvic organ prolapse, and adenomyosis. The MCP was determined by endometrial histology, confirmed by estradiol and progesterone serum levels and corroborated by 2 independent bioinformatics methods: clustering in unsupervised whole-transcriptome principal component analysis and cycle phase assignment classifier analysis. Patients with hormonal treatment within previous 3 months and presence of malignancy or major systemic disease were excluded.

B-CLL study 5 / normal bone marrow sample

Relative Expression (log2-ratio):3.7775526
Number of Samples:441 / 74
Experimental B-CLL study 5
Bone marrow samples of patients with B-cell chronic lymphocytic leukemia (B-CLL).
Control normal bone marrow sample
Non-leukemic and healthy bone marrow sample.

B-CLL study 11 (DMSO) / vehicle (DMSO) treated normal T-cell sample

Relative Expression (log2-ratio):3.582057
Number of Samples:4 / 4
Experimental B-CLL study 11 (DMSO)
Peripheral blood mononuclear cells (PBMCs) obtained from chronic lymphocytic leukemia (CLL) patients and in vitro treated with vehicle (DMSO) for 4 hours. PBMCs’ samples contained 90% CD19+ CD5+ B lineage CLL cells (B-CLL). Inclusion criteria: untreated CLL patients or at least 1 month after chemotherapy. Exclusion criteria: patients with active infections or other serious medical conditions or with white blood cell (WBC) counts of 15,000/l.
Control vehicle (DMSO) treated normal T-cell sample
MACS purified T-cells from healthy donor peripheral blood treated with vehicle (DMSO) for 4 hours.

uterine/pelvic pathology study 2 (pro. MCP) / uterine/pelvic pathology study 2 (early se MCP)

Relative Expression (log2-ratio):-3.4127235
Number of Samples:15 / 6
Experimental uterine/pelvic pathology study 2 (pro. MCP)
Endometrial tissue samples collected from women with uterine/pelvic pathology in the proliferative menstrual cycle phase (MCP). The group contained cycling women 20 – 50 years old with symptomatic uterine fibroids, pelvic organ prolapse, and adenomyosis. The MCP was determined by endometrial histology, confirmed by estradiol and progesterone serum levels and corroborated by 2 independent bioinformatics methods: clustering in unsupervised whole-transcriptome principal component analysis and cycle phase assignment classifier analysis. Patients with hormonal treatment within previous 3 months and presence of malignancy or major systemic disease were excluded.
Control uterine/pelvic pathology study 2 (early se MCP)
Endometrial tissue samples collected from women with uterine/pelvic pathology in the early secretory menstrual cycle phase (MCP). The group contained cycling women 20 – 50 years old with symptomatic uterine fibroids, pelvic organ prolapse, and adenomyosis. The MCP was determined by endometrial histology, confirmed by estradiol and progesterone serum levels and corroborated by 2 independent bioinformatics methods: clustering in unsupervised whole-transcriptome principal component analysis and cycle phase assignment classifier analysis. Patients with hormonal treatment within previous 3 months and presence of malignancy or major systemic disease were excluded.

endometriosis study 7 (pro. MCP) / endometriosis study 7 (early se MCP)

Relative Expression (log2-ratio):-3.3161259
Number of Samples:6 / 6
Experimental endometriosis study 7 (pro. MCP)
Endometrial tissue samples from women with moderate or severe endometriosis collected in the proliferative menstrual cycle phase (MCP). The tissue samples were obtained from normally cycling women with histologically confirmed, moderate-severe endometriosis by laparoscopy. The diagnosis was defined according to the revised American Fertility Society classification system. Patients using any hormonal treatment within 3 months were not included.
Control endometriosis study 7 (early se MCP)
Endometrial tissue samples from women with moderate or severe endometriosis collected in the early secretory menstrual cycle phase (MCP). The tissue samples were obtained from normally cycling women with histologically confirmed, moderate-severe endometriosis by laparoscopy. The diagnosis was defined according to the revised American Fertility Society classification system. Patients using any hormonal treatment within 3 months were not included.

Langerhans cell histiocytosis study 1 / normal epidermal Langerhans cell sample

Relative Expression (log2-ratio):-3.2093048
Number of Samples:7 / 3
Experimental Langerhans cell histiocytosis study 1
Langerhans cell histiocytes (LCH) were isolated from LCH lesions of patients undergoing surgery. All patients had single system disease, five patients had bone lesion, one had skin lesion and one had mucosal manifestation. Langerhans cells histiocytes were purified by FACS as CD1a+ / CD270 + population with > 95% purity.
Control normal epidermal Langerhans cell sample
Normal epidermal Langerhans cells were isolated from skin of healthy adult donors. Single cells were isolated by collagenase digestion from epidermal sheets and CD1a - expressing cells were isolated by FACS purification. Gene-chips were further analyzed for transcripts of potentially contaminating cells - no transcripts for CD3ε (T cell), CD19 (B cell) or Desmogleins 1-4 (keratinocytes) were detected, confirming purity of sorted cells.

DLBCL study 1 (activated B-cell like; naïve-like) / DLBCL study 1 (activated B-cell like; memory-like)

Relative Expression (log2-ratio):-3.2000551
Number of Samples:2 / 3
Experimental DLBCL study 1 (activated B-cell like; naïve-like)
Naive B-cells sorted from primary tumor samples from patients with malignant diffuse large B-cell lymphoma (activated B-cell like type). To isolate different B-cell subsets, tonsil tissues from DLBCL patients were sorted by fluorescence-activated cell sorting. Samples were also classified based on subset-specific B-cell-associated gene signature (BAGS).
Control DLBCL study 1 (activated B-cell like; memory-like)
Memory B-cells sorted from primary tumor samples from patients with malignant diffuse large B-cell lymphoma (activated B-cell like type). To isolate different B-cell subsets, tonsil tissues from DLBCL patients were sorted by fluorescence-activated cell sorting. Samples were also classified based on subset-specific B-cell-associated gene signature (BAGS).

endometriosis study 6 (moderate/severe endo.; mid-se MCP) / endometriosis study 6 (moderate/severe endo.; early se MCP)

Relative Expression (log2-ratio):-3.0951777
Number of Samples:19 / 12
Experimental endometriosis study 6 (moderate/severe endo.; mid-se MCP)
Endometrial tissue samples from women with moderate or severe endometriosis and pelvic pain and/or infertility collected in the mid-secretory menstrual phase cycle (MCP). Endometriosis was diagnosed based on the revised American Fertility Society classification system. The MCP was determined by endometrial histology, confirmed by estradiol and progesterone serum levels and corroborated by 2 independent bioinformatics methods: clustering in unsupervised whole-transcriptome principal component analysis and cycle phase assignment classifier analysis. Patients with hormonal treatment within previous 3 months and presence of malignancy or major systemic disease were excluded.
Control endometriosis study 6 (moderate/severe endo.; early se MCP)
Endometrial tissue samples from women with moderate or severe endometriosis and pelvic pain and/or infertility collected in the early secretory menstrual cycle phase (MCP). Endometriosis was diagnosed based on the revised American Fertility Society classification system. The MCP was determined by endometrial histology, confirmed by estradiol and progesterone serum levels and corroborated by 2 independent bioinformatics methods: clustering in unsupervised whole-transcriptome principal component analysis and cycle phase assignment classifier analysis. Patients with hormonal treatment within previous 3 months and presence of malignancy or major systemic disease were excluded

Organism: Homo sapiens
Gene: 38570_at
Selected probe(set): 205671_s_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array

Expression of 38570_at (205671_s_at) across 6674 perturbations tested by GENEVESTIGATOR:

CML study 1 / B-CLL study 5

Relative Expression (log2-ratio):-4.5167303
Number of Samples:75 / 441
Experimental CML study 1
Bone marrow samples of patients with chronic myeloid leukemia (CML).
Control B-CLL study 5
Bone marrow samples of patients with B-cell chronic lymphocytic leukemia (B-CLL).

ovulation study 1 / proliferative phase endometrium tissue

Relative Expression (log2-ratio):4.1840334
Number of Samples:3 / 4
Experimental ovulation study 1
Early secretory phase (ESE) endometrium tissue.
Control proliferative phase endometrium tissue
Proliferative phase (PE) endometrium tissue.

uterine/pelvic pathology study 2 (late se MCP) / uterine/pelvic pathology study 2 (early se MCP)

Relative Expression (log2-ratio):-4.1598177
Number of Samples:2 / 6
Experimental uterine/pelvic pathology study 2 (late se MCP)
Endometrial tissue samples collected from women with uterine/pelvic pathology in the late secretory menstrual cycle phase (MCP). The group contained cycling women 20 – 50 years old with symptomatic uterine fibroids, pelvic organ prolapse, and adenomyosis. The MCP was determined by endometrial histology, confirmed by estradiol and progesterone serum levels and corroborated by 2 independent bioinformatics methods: clustering in unsupervised whole-transcriptome principal component analysis and cycle phase assignment classifier analysis. Patients with hormonal treatment within previous 3 months and presence of malignancy or major systemic disease were excluded.
Control uterine/pelvic pathology study 2 (early se MCP)
Endometrial tissue samples collected from women with uterine/pelvic pathology in the early secretory menstrual cycle phase (MCP). The group contained cycling women 20 – 50 years old with symptomatic uterine fibroids, pelvic organ prolapse, and adenomyosis. The MCP was determined by endometrial histology, confirmed by estradiol and progesterone serum levels and corroborated by 2 independent bioinformatics methods: clustering in unsupervised whole-transcriptome principal component analysis and cycle phase assignment classifier analysis. Patients with hormonal treatment within previous 3 months and presence of malignancy or major systemic disease were excluded.

B-CLL study 5 / normal bone marrow sample

Relative Expression (log2-ratio):3.7775526
Number of Samples:441 / 74
Experimental B-CLL study 5
Bone marrow samples of patients with B-cell chronic lymphocytic leukemia (B-CLL).
Control normal bone marrow sample
Non-leukemic and healthy bone marrow sample.

B-CLL study 11 (DMSO) / vehicle (DMSO) treated normal T-cell sample

Relative Expression (log2-ratio):3.582057
Number of Samples:4 / 4
Experimental B-CLL study 11 (DMSO)
Peripheral blood mononuclear cells (PBMCs) obtained from chronic lymphocytic leukemia (CLL) patients and in vitro treated with vehicle (DMSO) for 4 hours. PBMCs’ samples contained 90% CD19+ CD5+ B lineage CLL cells (B-CLL). Inclusion criteria: untreated CLL patients or at least 1 month after chemotherapy. Exclusion criteria: patients with active infections or other serious medical conditions or with white blood cell (WBC) counts of 15,000/l.
Control vehicle (DMSO) treated normal T-cell sample
MACS purified T-cells from healthy donor peripheral blood treated with vehicle (DMSO) for 4 hours.

uterine/pelvic pathology study 2 (pro. MCP) / uterine/pelvic pathology study 2 (early se MCP)

Relative Expression (log2-ratio):-3.4127235
Number of Samples:15 / 6
Experimental uterine/pelvic pathology study 2 (pro. MCP)
Endometrial tissue samples collected from women with uterine/pelvic pathology in the proliferative menstrual cycle phase (MCP). The group contained cycling women 20 – 50 years old with symptomatic uterine fibroids, pelvic organ prolapse, and adenomyosis. The MCP was determined by endometrial histology, confirmed by estradiol and progesterone serum levels and corroborated by 2 independent bioinformatics methods: clustering in unsupervised whole-transcriptome principal component analysis and cycle phase assignment classifier analysis. Patients with hormonal treatment within previous 3 months and presence of malignancy or major systemic disease were excluded.
Control uterine/pelvic pathology study 2 (early se MCP)
Endometrial tissue samples collected from women with uterine/pelvic pathology in the early secretory menstrual cycle phase (MCP). The group contained cycling women 20 – 50 years old with symptomatic uterine fibroids, pelvic organ prolapse, and adenomyosis. The MCP was determined by endometrial histology, confirmed by estradiol and progesterone serum levels and corroborated by 2 independent bioinformatics methods: clustering in unsupervised whole-transcriptome principal component analysis and cycle phase assignment classifier analysis. Patients with hormonal treatment within previous 3 months and presence of malignancy or major systemic disease were excluded.

endometriosis study 7 (pro. MCP) / endometriosis study 7 (early se MCP)

Relative Expression (log2-ratio):-3.3161259
Number of Samples:6 / 6
Experimental endometriosis study 7 (pro. MCP)
Endometrial tissue samples from women with moderate or severe endometriosis collected in the proliferative menstrual cycle phase (MCP). The tissue samples were obtained from normally cycling women with histologically confirmed, moderate-severe endometriosis by laparoscopy. The diagnosis was defined according to the revised American Fertility Society classification system. Patients using any hormonal treatment within 3 months were not included.
Control endometriosis study 7 (early se MCP)
Endometrial tissue samples from women with moderate or severe endometriosis collected in the early secretory menstrual cycle phase (MCP). The tissue samples were obtained from normally cycling women with histologically confirmed, moderate-severe endometriosis by laparoscopy. The diagnosis was defined according to the revised American Fertility Society classification system. Patients using any hormonal treatment within 3 months were not included.

Langerhans cell histiocytosis study 1 / normal epidermal Langerhans cell sample

Relative Expression (log2-ratio):-3.2093048
Number of Samples:7 / 3
Experimental Langerhans cell histiocytosis study 1
Langerhans cell histiocytes (LCH) were isolated from LCH lesions of patients undergoing surgery. All patients had single system disease, five patients had bone lesion, one had skin lesion and one had mucosal manifestation. Langerhans cells histiocytes were purified by FACS as CD1a+ / CD270 + population with > 95% purity.
Control normal epidermal Langerhans cell sample
Normal epidermal Langerhans cells were isolated from skin of healthy adult donors. Single cells were isolated by collagenase digestion from epidermal sheets and CD1a - expressing cells were isolated by FACS purification. Gene-chips were further analyzed for transcripts of potentially contaminating cells - no transcripts for CD3ε (T cell), CD19 (B cell) or Desmogleins 1-4 (keratinocytes) were detected, confirming purity of sorted cells.

DLBCL study 1 (activated B-cell like; naïve-like) / DLBCL study 1 (activated B-cell like; memory-like)

Relative Expression (log2-ratio):-3.2000551
Number of Samples:2 / 3
Experimental DLBCL study 1 (activated B-cell like; naïve-like)
Naive B-cells sorted from primary tumor samples from patients with malignant diffuse large B-cell lymphoma (activated B-cell like type). To isolate different B-cell subsets, tonsil tissues from DLBCL patients were sorted by fluorescence-activated cell sorting. Samples were also classified based on subset-specific B-cell-associated gene signature (BAGS).
Control DLBCL study 1 (activated B-cell like; memory-like)
Memory B-cells sorted from primary tumor samples from patients with malignant diffuse large B-cell lymphoma (activated B-cell like type). To isolate different B-cell subsets, tonsil tissues from DLBCL patients were sorted by fluorescence-activated cell sorting. Samples were also classified based on subset-specific B-cell-associated gene signature (BAGS).

endometriosis study 6 (moderate/severe endo.; mid-se MCP) / endometriosis study 6 (moderate/severe endo.; early se MCP)

Relative Expression (log2-ratio):-3.0951777
Number of Samples:19 / 12
Experimental endometriosis study 6 (moderate/severe endo.; mid-se MCP)
Endometrial tissue samples from women with moderate or severe endometriosis and pelvic pain and/or infertility collected in the mid-secretory menstrual phase cycle (MCP). Endometriosis was diagnosed based on the revised American Fertility Society classification system. The MCP was determined by endometrial histology, confirmed by estradiol and progesterone serum levels and corroborated by 2 independent bioinformatics methods: clustering in unsupervised whole-transcriptome principal component analysis and cycle phase assignment classifier analysis. Patients with hormonal treatment within previous 3 months and presence of malignancy or major systemic disease were excluded.
Control endometriosis study 6 (moderate/severe endo.; early se MCP)
Endometrial tissue samples from women with moderate or severe endometriosis and pelvic pain and/or infertility collected in the early secretory menstrual cycle phase (MCP). Endometriosis was diagnosed based on the revised American Fertility Society classification system. The MCP was determined by endometrial histology, confirmed by estradiol and progesterone serum levels and corroborated by 2 independent bioinformatics methods: clustering in unsupervised whole-transcriptome principal component analysis and cycle phase assignment classifier analysis. Patients with hormonal treatment within previous 3 months and presence of malignancy or major systemic disease were excluded